Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Bigger animals have increased cancer risk, study confirms
Elephants' rapid evolution has meant they have managed to reduce their cancer risk.
Findings challenge belief that there is no link with size.

A study has challenged long-standing theories by revealing that larger animals do have an increased risk of developing cancer.

The findings challenge the idea of ‘Peto’s paradox’: a theory from 1977 that suggested that there was no correlation between animal size and cancer risk.

The new study saw researchers from three universities collaborate to examine cancer data from 263 species. This was spread across the four major animal groups: amphibians, birds, mammals and reptiles.

The data had been gathered from veterinary autopsies of 31 amphibians, 79 birds, 90 mammals and 63 reptiles. Using advanced statistical methods, researchers analysed the relationship between cancer rates and body sizes, while taking into account the different species involved.

Researchers discovered that, overall, bigger animals displayed a higher prevalence of benign and malignant tumours.

This finding proved to be consistent in all species, regardless of whether they naturally stop growing (birds and mammals) or grow throughout their lives (amphibians and reptiles).

However, the researchers also identified that rapid evolution was a contributing factor to cancer defence. Animals which have rapidly evolved to a large size over short evolutionary timescales also evolved improved mechanisms to control cell growth and prevent tumours.

This means that, despite being ten times bigger, elephants have approximately the same cancer risk as a tiger.

There were some outliers to the researchers’ theory though, where a subset of species had much more or much less cancer than expected for their body size.

The common budgie, which weighs less than 30g, was found to have cancer rates which were more than 40 times higher than expected for its body size. The naked mole rat, however, had almost no recorded rate of cancer.

Advances in modern medicine means that researchers were unable to apply this theory to humans.

Overall, the research revealed a trend of larger species recording higher cancer rates. However, it also highlighted the role of evolution in developing mechanisms for cellular defence.

George Butler, lead author of the research at University College London, said: “Finding which animals are naturally better at fighting off cancer opens exciting new paths for research.

“By studying these successful species, we can better understand how cancers develop and potentially discover new ways to fight the disease. This could lead to breakthrough treatments in the future."

The full study can be found in the journal Proceedings of the National Academy of Sciences.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.